Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oralgen Grass Pollen dose-ranging study in grass pollen allergic rhinoconjunctivitis
2006-001548-30Phase 2Completed
- Sponsor
- Artu Biologicals
- Start
- Aug 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Oralgen Grass Pollen in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Artu Biologicals. Primary endpoint: Pollen Season RTSS (PS.RTSS). Started Aug 2006; status: completed.
02
Drugs
Oralgen Grass Pollen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2006-001548-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001548-30.